Drug intelligence / Profile preview

S1-221

Development stage: Phase 1
Lead developer: Delphian Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

S1-221 is an investigational oral liquid **cannabinoid combination** developed by Delphian Therapeutics for the acute treatment of migraine. It contains cannabidiol and delta-9-tetrahydrocannabinol and has been evaluated in a first-in-human Phase 1 single-ascending-dose study in healthy adults to characterize safety, tolerability, pharmacokinetics, acute subjective effects, and exploratory effects on plasma endocannabinoid levels. Dose selection from this study is intended to support subsequent migraine efficacy studies.

Other names: CBD + THCcannabidiol + delta-9-tetrahydrocannabinol

Targets

CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on S1-221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S1-221.

Explore the full profile